These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 16829185

  • 1. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
    Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M.
    Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
    [Abstract] [Full Text] [Related]

  • 2. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS, Cleland JG, Eha J, Belenkov Y, Kivikko M, Põder P, Sarapohja T.
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [Abstract] [Full Text] [Related]

  • 3. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
    Branzi G, Malfatto G, Villani A, Ciambellotti F, Revera M, Giglio A, Rosa FD, Facchini M, Parati G.
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
    [Abstract] [Full Text] [Related]

  • 4. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E, Erturk M, Birant A, Kurtar Mansıroglu A, Akturk IF, Karakurt H, Yalcin AA, Uzun F, Somuncu MU, Yildirim A.
    Cardiol J; 2015 Sep; 22(1):87-93. PubMed ID: 24846511
    [Abstract] [Full Text] [Related]

  • 5. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT.
    Am J Cardiol; 2006 Jul 01; 98(1):102-6. PubMed ID: 16784930
    [Abstract] [Full Text] [Related]

  • 6. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
    Hou ZQ, Sun ZX, Su CY, Tan H, Zhong X, Hu B, Zhou Y, Shang DY.
    Cardiovasc Ther; 2013 Apr 01; 31(2):108-14. PubMed ID: 23490237
    [Abstract] [Full Text] [Related]

  • 7. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F.
    Ital Heart J; 2003 May 01; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
    Sargento L, Brito D, Matias JS, Madeira H.
    Rev Port Cardiol; 2007 May 01; 26(7-8):717-26. PubMed ID: 17939581
    [Abstract] [Full Text] [Related]

  • 14. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM, Thomas MD, Dembo L, Best M, Driscoll GO.
    Heart Lung Circ; 2008 Jun 01; 17(3):206-10. PubMed ID: 18242130
    [Abstract] [Full Text] [Related]

  • 15. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
    Giamouzis G, Giannakoulas G, Tsarpalis K, Agha SA, Georgiopoulou V, Kalogeropoulos A, Karvounis H, Butler J.
    Int J Cardiol; 2008 Aug 01; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
    [No Abstract] [Full Text] [Related]

  • 16. [Possibilities of using levosimendan in patients with idiopathic pulmonary hypertension].
    Martyniuk TV, Arkhipova OA, Kobal' EA, Danilov NM, Chazova IE.
    Ter Arkh; 2012 Aug 01; 84(9):83-8. PubMed ID: 23091860
    [Abstract] [Full Text] [Related]

  • 17. Effects of levosimendan on right ventricular function in patients with advanced heart failure.
    Parissis JT, Paraskevaidis I, Bistola V, Farmakis D, Panou F, Kourea K, Nikolaou M, Filippatos G, Kremastinos D.
    Am J Cardiol; 2006 Dec 01; 98(11):1489-92. PubMed ID: 17126656
    [Abstract] [Full Text] [Related]

  • 18. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG, Nikitin N, McGowan J.
    Expert Rev Cardiovasc Ther; 2004 Jan 01; 2(1):9-19. PubMed ID: 15038409
    [Abstract] [Full Text] [Related]

  • 19. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
    Cetin M, Uçar O, Cicekçioğlu H, Güven Cetin Z, Sahin M, Vasfi Ulusoy F, Aydoğdu S.
    Acta Cardiol; 2012 Jun 01; 67(3):317-23. PubMed ID: 22870740
    [Abstract] [Full Text] [Related]

  • 20. A struggle to SURVIVE: to abandon or not to abandon levosimendan?
    Butler J, Giamouzis G, Giannakoulas G.
    Cardiovasc Drugs Ther; 2007 Oct 01; 21(5):401-2. PubMed ID: 17701453
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.